短链脂肪酸在多发性硬化症中的免疫调节潜力
Laura Barcutean1, Smaranda Maier1, Mihai Burai-Patrascu2
1Neurology Department, University of Medicine, Pharmacy, Science and Technology "George Emil Palade" Targu Mures, 540142 Targu Mures, Mures, Romania.
International journal of molecular sciences
|March 28, 2024
概括
短链脂肪酸 (SCFA) 可能为多发性硬化症 (MS) 提供治疗潜力. 这些化合物调节肠-大脑轴和免疫反应,有可能在这种慢性中枢神经系统疾病中恢复平衡.
科学领域:
- 神经免疫学 神经免疫学
- 微生物组研究 微生物组研究
- 神经退行性疾病 神经退行性疾病
背景情况:
- 多发性硬化症 (MS) 是一种慢性中枢神经系统疾病,涉及炎症,脱髓化和神经退行.
- 自动反应性T淋巴细胞穿越血脑屏障 (BBB) 和肠道失生症都与MS的发病有关.
- 支持炎症的Th1/Th17细胞和调节性T细胞在MS中出现的免疫失衡中发挥着关键作用.
研究的目的:
- 审查短链脂肪酸 (SCFA) 在治疗多发性硬化症方面的治疗潜力.
- 探索SCFA在调节肠-大脑轴和与MS相关的免疫反应中的作用.
- 要突出SCFA如何恢复免疫平衡并影响MS中的BBB透性.
主要方法:
- 文献综述侧重于肠道微生物群和SCFA在MS中的作用.
- 对研究SCFA产生,免疫调节和对中枢神经系统的影响的研究进行分析.
- 检查SCFA,监管T细胞和BBB完整性之间的相互作用.
主要成果:
- 肠道微生物群失调有助于全身炎症,并与MS有关.
- 酸,特别是酸和酸,具有显著的抗炎性质.
- SCFA 显示出影响调控性 T 细胞分化和 BBB 透性的能力.
结论:
- 在多发性硬化症中,SCFA是一种有前途的治疗途径.
- 通过SCFA调节准肠-大脑轴可以恢复多发性硬化症患者的免疫平衡.
- 对基于SCFA的治疗方法的进一步研究可能会为MS患者带来新的治疗方法.
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162


